Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Phase 1 Completed 5 enrolled Dana-Farber Cancer Institute National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Treatment of the donor bone marrow with the patient's white blood cells and a monoclonal antibody may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of bone marrow transplantation with specially treated bone marrow in treating patients who have hematologic cancer that has not responded to previous therapy.

Timeline

Start: 2000-02
Primary completion: 2001-06-16
Completion: 2002-03-08

Publications

Background Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008 Sep 15;112(6):2232-41. doi: 10.1182/blood-2008-03-143636. Epub 2008 Jul 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Cyclosporine	Peptide	—	Intravenous
Background	Leucovorin	Small molecule	—	Intravenous
Background	Methotrexate	Small molecule	—	Intravenous
Background	Methylprednisolone	Other / unclassified	—	Intravenous

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Summary

Timeline

Publications

Drugs

Indications